Information Provided By: 
Fly News Breaks for March 30, 2017
NLNK
Mar 30, 2017 | 07:39 EDT
As noted earlier, SunTrust upgraded NewLink to Buy from Hold. As reasons for the upgrade, SunTrust analyst Peter Lawson cited the company's expansion into the melanoma indication, its attractive risk/reward ratio versus other IDO molecule drug makers , and his belief that the company is "well-positioned as an M&A target." Price target to $30 from $12.
News For NLNK From the Last 2 Days
There are no results for your query NLNK
